by Cynthia Robbins-roth
|
| List Price: | $17.50 |
| Amazon Price: | $11.90 & eligible for FREE Super Saver Shipping on orders over $25. |
| You Save: | $5.60 (32%) |
| Average Rating: |  |
| Lowest New Price: | $6.19 |
| Availablitiy: | Usually ships in 24 hours |
|
 |
|
Product Description
"A tour-de-force for anyone who is interested in the biotech industry. I applaud the enormous achievement of Cynthia Robbins-Roth."-Frederick Frank, Senior Managing Director & Vice Chair, Lehman Brothers"From Alchemy to IPO tells the dramatic story of this revolutionary industry as only an insider can."-George Rathmann, President and CEO, ICOS Corporation, Chairman Emeritus, AmgenWritten by a well-known industry insider, From Alchemy to IPO addresses the coming-of-age of biotech products and companies and traces the history of biotechnology from its early inception in the seventies to today's heyday of new solutions and breakthrough treatments. It describes the amazing entrepreneurial trail of product development, novel business models, and critical trials that eventually pave the way to market. This is the first book to accurately record the inner workings of an industry-biotechnology-that's on the verge of living up to its monumental promise to change the world as we know it.
Amazon
Despite unnerving swings in individual stock valuations--or perhaps because of them--many knowledgeable observers still believe the 21st century will ultimately earn its stripes as the Age of Biotech. Cynthia Robbins-Roth, named by Forbes magazine as one of the industry's top insiders, certainly is among them. And in From Alchemy to IPO, she persuasively argues investors better take heed because they ain't seen nothin' yet. "Most of us think of biotech as medicine or genetically engineered crops," writes Robbins-Roth. But in the very near future, she continues, it also "may make it possible for humans to reach the stars and to change the environment on other planets." Think that's far-fetched? She says developments like this are already in early stages and, in a deliberately proselytizing manner, traces their roots to the current business nitty-gritty, finally focusing on the long-term moneymaking potential. "The biotech world will never be an easy place for investors," she cautions, but with hundreds of ongoing projects "poised to power into the marketplace," there will be plenty of "opportunities for investors and employees alike." Recommended for readers seeking an informed tutorial on this field of the future. --Howard Rothman
Customers who bought this item also bought
Average Customer Review:
2 of 2 people found the following review helpful:
Good introductory text and overview of the industry, 2005-03-06
I read From Alchemy to IPO for an MBA course on entrepreneurialism in the pharmaceutical industry. Given my background (undergraduate business, financial analyst role, limited in-depth scientific knowledge), I found this book to be a very useful and balanced guide to both the business and technical aspects of biotechnology.
Robbins-Roth includes enough information on initial public offerings (IPOs) and merger activity among biotech firms to warm the hearts of the most resolute business student, but the drug discovery and development process is also covered in sufficient detail to give the lay reader an understanding for the operational challenges faced by firms in this sector.
Add to this the competent yet necessarily superficial descriptions of more esoteric terms such as monoclonal antibodies and combinatorial chemistry, and you have a solid text that covers the industry and its ongoing challenges very well.
1 of 2 people found the following review helpful:
Brilliant Overview, 2004-05-31
This is a great overview of the world of biotech. The author explains the science with clarity and enthusiasm and the introduction this book provides to the corporate side of biotech is also very interesting and well written.
1 of 4 people found the following review helpful:
 bad writing, 2004-01-15
I read the first 20 pages of this book and quit. It was too painful to keep going. The author's wording in convoluted, tangential, and just plain annoying. She throws out dozens of names from the industry, so many you can't keep them straight. There is poor flow to the writing, so you cannot understand why she is telling you things from one line to the next. The topics of each paragraph jump from one subject to another with abrupt, confusing transitions. I returned the book!
4 of 4 people found the following review helpful:
 Clear and non hyped intro into biotech, 2002-05-28
I'll be starting a biomedical engineering Ph.D. program in the fall and have read recently a few books on the biotech subject. This one gave the clearest picture of the biotech industries, the companies in them, how to manage and finance them, as well as how to recognize solid biotech companies for investing purposes. A quick and entertaining read for anyone interested in the business behind biotechnology.
12 of 16 people found the following review helpful:
WAY OVERRATED BOOK ON BIOTECH, 2001-08-25
to quote another user: "The author's expertise in science, finance, management strategy, and journalism..." the author can write decently and she may know about biotech (hard to judge for me not being a scientist)...BUT her knowledge about management strategy and finance is limited at best...that wouldn't be so bad if she were to stick to write about science...however, she thinks she knows about finance and strategy...who wants to read about strategy should stick with hamel, pralahad, porter etc., who wants to read about finance (valuation) should stick with copeland et al, and who wants to read about ipos should try articles by jay ritter.
Price is accurate as of the date/time indicated. Prices and product availability are subject to change. Any price displayed on the Amazon website at the time of purchase will govern the sale of this product.
|
Store Categories
|